Shots:
- The P-II trial consists of 4 overlapping stages: Stage 1 (vs PBO) for tilrekimig & ompekimig; Stage 2 (dose-ranging) & Stage 3 (ongoing) evaluated tilrekimig, with Stage 3 involving biologic-experienced adults; Stage 4 is an ongoing ompekimig dose-ranging study
- Trial met its 1EP with more pts achieving EASI-75 at Wk. 16; PBO-adjusted rates were 38.7% (low), 51.9% (mid), & 49.4% (high dose), while Stage 2 (QM dosing) showed competitive efficacy, with higher doses suggesting meaningful improvement
- Tilrekimig is also being evaluated in an ongoing P-II study in asthma & a recently initiated P-IIb/III trial in COPD, while P-III planning in AD is underway with a pivotal study expected to begin this year
Ref: Pfizer | Image: Pfizer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
